Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06627751 · ClinicalTrials.gov registry record · Phase 2
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
A Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06627751 is a Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 28 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06627751, a Phase 2 study of Refractory Multiple Myeloma and Recurrent Multiple Myeloma, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \[EMD\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- DRUG Dexamethasone
- DRUG Carfilzomib
- PROCEDURE Echocardiography
- BIOLOGICAL Mezigdomide
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2030-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06627751
The ClinicalTrials.gov registry entry for NCT06627751 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (42% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT06627751 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06627751 about?
NCT06627751 is a clinical study titled "Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease". This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone...
What is the current status of trial NCT06627751?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-05-01. Estimated completion is 2030-05-01.
What conditions does trial NCT06627751 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Recurrent Multiple Myeloma, Extramedullary Disease in Multiple Myeloma.
What interventions are being tested in trial NCT06627751?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Dexamethasone (DRUG), Carfilzomib (DRUG), Echocardiography (PROCEDURE), Mezigdomide (BIOLOGICAL).
Who is sponsoring clinical trial NCT06627751?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06627751 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
RECRUITING · Phase 2
-
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
RECRUITING · Phase 2
-
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.